Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Indigenously Developed Freeze Dried Cold Kit and Biological Response in In-Vitro and In-Vivo Models
Somatostatin receptors (SStR) based 177 Lu-DOTATATE therapy is known as one of the highly effective neuroendocrine tumors (NETs) treatment strategy. Development of DOTATATE freeze-dried kit for imaging and therapy of SStR positive NETs is a prime goal in neuroendocrine cancer research. The present w...
Main Authors: | Samina Roohi, Shakera Khatoon Rizvi, Syed Ali Raza Naqvi |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-02-01
|
Series: | Dose-Response |
Online Access: | https://doi.org/10.1177/1559325821990147 |
Similar Items
-
A Clinical Guide to Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE in Neuroendocrine Tumor Patients
by: Morticia N. Becx, et al.
Published: (2022-11-01) -
Evaluation of Kidney Dose in Neuroendocrine Tumors Patients after Peptide Receptor Radionuclide Therapy using 177Lu-DOTATATE
by: N.R. Hidayati, et al.
Published: (2019-12-01) -
Acquisition Conditions for Lu-177 DOTATATE Imaging
by: Yuri Sagisaka, et al.
Published: (2024-01-01) -
Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup>Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms
by: Ulrika Jahn, et al.
Published: (2021-02-01) -
Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough
by: Hinke Siebinga, et al.
Published: (2022-12-01)